Finding a treatment or a cure for Alzheimer’s disease is keeping researchers busy across the world. Unfortunately, they aren’t having a lot of success and the latest hopeful entry has turned out to be a bust.
Dimebon, a medication that was developed to help slow the progression of Alzheimers has failed in the latest round of testing of 598 patients with mild to moderate disease. The results shocked the researchers because an earlier, smaller 18-month study of the drug showed that there was improvement among the patients taking Dimebon.
The companies that collaborated on the production, Pfizer and Medivation, haven’t given up completely on the drug. They are continuing with four more studies that combine Dimebon with other drugs, as well as one study that is investigating its usefulness in treating Huntingdon’s disease.
Alzheimer’s disease usually strikes people over the age of 65 years, but is also found in younger people. Called early-onset Alzheimer’s, the disease appears to progress much more quickly than with the more common older-onset.